News ArchivesRead News
Your Weekly Parkinson's News Update for the Week of 2.25.19
Monday February 25, 2019
Your Weekly Parkinson's News Update for the Week of 2.25.19 -
A new study by Scuola Internazionale Superiore di Studi Avanzati concludes that people treated with deep brain stimulation (DBS) of the subthalamic nucleus don't always make more impulsive decisions than others: "Our study confirms that patients with DBS are no more impulsive in this kind of situation and they do not try to find gratifications more hastily than the others. Moreover, for the first time, we have demonstrated that this does not even depend on the type of reward offered to them".
A year after AbbVie and Voyager Therapeutics teamed up on Alzheimer’s, they are expanding their partnership to include Parkinson’s and other conditions in which misfolded alpha-synuclein protein builds up in the brain.
Voyager's vectorized antibody platform is designed to tackle the challenge of getting enough antibodies across the blood-brain barrier to bring about a therapeutic effect.
"Under the expanded deal, Voyager will carry out research and preclinical development to 'vectorize' antibodies against alpha-synuclein that are chosen by AbbVie, the companies said in a statement."
ABC10 News San Diego
"San Diego resident Jenifer Raub describes herself as a fighter.
'I just don’t give up. If I see a window, just a little crack in the doorway of opportunity, I’m going to jump on it,' said Raub. She never imagined to find herself in the fight against Parkinson's.
So Raub shifted her fight towards finding a cure for Parkinson's.
She's now president of the Summit for Stem Cell Foundation, a nonprofit created to support the use of stem cells to treat Parkinson’s; research is underway in Dr. Jeanne Loring’s Torrey Pines lab.
'We’re right on the edge of a revolution, in which these particular cells, because of their power and our ability to manipulate them, are going to change the way medicine is done,' said Dr. Loring. Her research focuses on pluripotent stem cells, the remarkable cells that self-renew and can give rise to every cell type in the body."
New Zealand Herald
Along with the Silverstein Foundation, The Michael J. Fox Foundation put $226,000 towards a New Zealand-based research project that focuses on a specific gene involved is called glucocerebrosidase beta acid, or GBA.
"Research has already shown how GBA mutations hamper an enzyme that helps clean out degraded or excess cell parts, before they can build up to cause the damage seen in Parkinson's. The new study, led by University of Auckland Associate Professor Justin O'Sullivan, will draw on a powerful 3D genome-mapping tool created to reveal the connections of GBA to other genes.
Researchers think parts of the gene may be acting as 'DNA switches' and disrupting the functioning of other genes that GBA comes into contact with through the way DNA is coiled inside cells."
Recent NewsMay 18 - Your Parkinson's News Update for the Week of 5.18.20
May 11 - Your Parkinson's News Update for the Week of 5.11.20
May 4 - Your Parkinson's News Update for the Week of 5.4.20
Apr 27 - News Update for the Week of 4.27.20
Apr 20 - News Update for the Week of 4.20.20
Apr 13 - Your Weekly Parkinson's News Update for the Week of 4.13.20
Apr 6 - News Update for the Week of 4.6.20
Mar 30 - Your Weekly Parkinson's News Update for the Week of 3.30.20
Mar 23 - News Update for the Week of 3.23.20
Mar 16 - News Update for the Week of 3.16.20
Mar 9 - News Update for the Week of 3.9.20
Mar 2 - News Update for the Week of 3.2.20
Feb 24 - News Update for the Week of 2.24.20
Feb 17 - News Update for the Week of 2.17.20
Feb 10 - News Update for the Week of 2.10.20
Feb 3 - News Update for the Week of 2.3.20
Jan 27 - News Update for the Week of 1.27.20
Jan 20 - Update for the Week of 1.20.20
Jan 13 - Your Parkinson's Weekly News Update for the Week of 1.13.20
Jan 6 - Your Weekly News Update for the Week of 1.6.20